Given that canonical metabolic drugs may also harm normal cells, the combination of AURKA inhibitors with L-asparaginase, as reported in a recent study for KEAP1 mutant lung cancer [48], holds promise for achieving enhanced therapeutic efficacy and merits further investigation. The gene discussed is AURKA; the disease is lung carcinoma.